The Cancer/Tumor Profiling Market is projected to reach $22.3 billion by 2030, at a CAGR of 20.9% during the forecast period, says Meticulous Research®. In recent years, the evolution of precision oncology, which involves matching the right treatment to the right patient at the right time, has significantly advanced cancer care. Studies from 2001 to 2020 indicate that cancer mortality rates have declined by approximately 27%. The success in these outcomes is mainly attributed to the use of targeted therapies that combat specific gene mutations driving the cancer, in contrast to the traditional one-size-fits-all approach of chemotherapy. For instance, there has been a sharp increase in targeted treatments for individuals with advanced lung cancer, with more than 15 FDA approvals since 2020.
Oncologists and pathologists are increasingly adopting cancer/tumor profiling to enhance their capabilities in identifying actionable biomarkers that can precisely match patients undergoing clinical trials and precision therapies. The growth of the cancer/tumor profiling market is driven by the increasing prevalence of cancer, advancements in multi-omics tumor profiling and cancer research, rising R&D investments by pharmaceutical and biotechnology companies for biomarker development, government initiatives aimed at reducing cancer mortality, and the utilization of biomarkers in tumor profiling.
Here are the top 10 companies operating in the Cancer/Tumor Profiling Market
Illumina, Inc. (U.S.)
Incorporated in 1998 and headquartered in California, U.S., Illumina is a provider of sequencing- and array-based solutions for genomic and genetic analysis. The company operates through two reportable segments: Core Illumina and GRAIL. The Core Illumina segment offers cancer/tumor profiling solutions to simplify profiling and accelerate analysis.
Illumina provides its solutions to government laboratories, genomic research centers, academic institutions, hospitals, commercial molecular diagnostics laboratories, and pharmaceutical and consumer genomics companies. The company has manufacturing sites and laboratories in the U.S., Singapore, and the U.K.
Illumina distributes its products across North America, Europe, Latin America, Asia-Pacific, and the Middle East & Africa through its distributors. Some of its subsidiaries are Illumina GmbH (Germany), Illumina Australia Pty. Ltd. (Australia), Illumina UK, Ltd. (U.K.), Illumina Italy S.r.l. (Italy), Illumina Netherlands B.V. (Netherlands) and Illumina K.K. Japan (Japan).
Thermo Fisher Scientific Inc. (U.S.)
Founded in 1956 and headquartered in Massachusetts, U.S., Thermo Fisher offers products and services in the pharmaceutical, biotechnology, agricultural, clinical, healthcare, government, and academic sectors. The company operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Biopharma Services.
Thermo Fisher has a strong geographical presence across North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa through its subsidiaries, R&D sites, and a distribution network. As of December 2022, the company had a headcount of 130,000 employees, of which 67,000 were employed in the Americas, 21,000 in Asia-Pacific, and 42,000 in Europe and the Middle East & Africa.
Some of its major subsidiaries are Thermo Fisher Germany B.V (Netherlands), Thermo Fisher Scientific (Mexico City) LLC (U.S.), Thermo Fisher Scientific Oy (Finland), Thermo Fisher Scientific FLC LLC (U.S.), and Thermo Fisher Scientific Australia Pty Ltd (Australia).
QIAGEN N.V. (Netherlands)
Founded in 1984 and headquartered in Venlo, Netherlands, QIAGEN N.V. is one of the leading providers of sample and assay technologies for molecular diagnostics, applied testing, and academic and pharmaceutical research. The company offers its products through only one reportable segment and provides them in two major markets: Molecular Diagnostics and Life Sciences.
QIAGEN’S product offerings include diagnostics solutions, PCR products, genomic or NGS products, consumables, and instruments for sample technologies. The company offers more than 500 core products consisting of instruments, kits, bioinformatics solutions, and a wide range of NGS services, such as RNA sequencing services, DNA sequencing services, whole genome amplification services, and RNA isolation services.
The company markets its products in more than 130 countries. The company has facilities located in the U.S., China, Germany, Poland, the Philippines, Denmark, Romania, Spain, the U.K., and other countries. Furthermore, the company’s sales are handled by distributors and sales subsidiaries. It also sells products directly to customers. In the Americas, Europe, Asia, and Australia, the sales are mainly taken care of by the subsidiaries.
Some of the key subsidiaries of the company are Qiagen AB (Sweden), Qiagen AG (Sweden), Qiagen GmbH (Germany), QIAGEN LLC (U.S.), QIAGEN China (Shanghai) Co. Ltd. (China), QIAGEN Inc. (Canada), QIAGEN K.K. (Japan), and QIAGEN S.r.l. (Italy). As of December 2020, the company had employed over 902 personnel for R&D.
F. Hoffmann-La Roche Ltd (Switzerland)
Founded in 1896 and headquartered in Basel, Switzerland, Roche is a healthcare company that develops, manufactures, and markets a wide range of healthcare solutions. The company operates through two reportable divisions, namely, Pharmaceuticals and Diagnostics, of which the Diagnostics division operates in the cancer/tumor profiling market.
The Diagnostics division is engaged in developing a wide range of diagnostic products and solutions such as in vitro diagnostics solutions, molecular diagnostics, clinical chemistry & immunoassays, point-of-care testing, tissue diagnostics, patient self-testing, next-generation sequencing, laboratory automation and IT, and decision support solutions.
Roche has a geographical presence across the U.S., Germany, Switzerland, Japan, China, India, New Zealand, Australia, Latin America, and Africa. Furthermore, the company has 23 manufacturing sites and 29 research and development sites worldwide.
Some of its subsidiaries are Roche Diagnostics (U.S.), Roche Diagnostics GmbH (Germany), Roche Diagnostics France SAS (France), Roche Diagnostics S.p.A. (Italy), Roche Diagnostics International AG (Switzerland), Roche Diagnostics Limited (U.K.), Roche Diagnostics (Shanghai) Ltd. (China), and Roche Diagnostics K.K (Japan).
Agilent Technologies, Inc. (U.S.)
Founded in 1999 and headquartered in California, U.S., Agilent Technologies provides application-focused solutions to the life sciences, diagnostics, and applied chemical markets. The company operates through three business segments: Life Sciences and Applied Markets; Agilent CrossLab; and Diagnostics and Genomics.
Agilent Technologies has a geographical presence across North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa, and customers in over 110 countries through its subsidiaries and a strong distribution network. The company has research & development and manufacturing sites in the U.S., Australia, China, Denmark, Germany, Italy, Japan, Malaysia, Singapore, and the U.K.
Some of the company’s subsidiaries are Agilent Technologies Canada Inc. (Canada), Agilent Technologies UK Limited (U.K.), Agilent Technologies Deutschland GmbH (Germany), Agilent Technologies Company Limited (China), Agilent Technologies Japan, Ltd (Japan), Agilent Technologies Brasil Ltda. (Brazil), and Agilent Technologies France SAS (France).
Meticulous Research in its latest publication on Cancer/Tumor Profiling Market has predicted the growth of 20.9% during the forecast year 2023-2030.
NanoString Technologies, Inc. (U.S.)
Incorporated in 2003 and headquartered in Washington, U.S., NanoString Technologies, Inc. is a life sciences company that manufactures and markets solutions for researchers, mainly in the field of proteomics and genomics. The company operates through one reportable business segment: ‘Development, Manufacture and Commercialization of Instruments, Consumables and Services,’ and reports its earnings based on Product Revenue and Service Revenue.
NanoString has a geographical presence across North America, Europe, and Asia-Pacific and serves its customers through its subsidiaries and a strong distribution network. The company has a research & development and manufacturing site in Seattle, U.S.
Some of the key subsidiaries of the company are NanoString Technologies Europe Limited (U.K.), NanoString Technologies SAS (France), NanoString Technologies International, Inc. (U.S.), NanoString Technologies Germany GmbH (Germany), NanoString Technologies (Bejing) Co. Ltd. (China), and NanoString Technologies Spain, S.L. (Spain).
HTG Molecular Diagnostics, Inc. (U.S.)
Founded in 1997 and headquartered in Arizona, U.S., HTG Molecular Diagnostics, Inc. is a company that focuses on offering solutions for expanding drug discovery and precision medicine through its advanced drug discovery and transcriptome-wide profiling platform technologies. The company operates through one business segment: Product and Product-related Services.
The company’s manufacturing site is situated in Arizona, U.S. It distributes its consumables and instruments directly in the U.S. while relying on a network of distributors for other European countries. The company has established a direct sales presence in Austria, Belgium, France, Germany, Luxembourg, the Netherlands, the U.K., and Switzerland. Additionally, it has distributors in Bulgaria, Croatia, Czech Republic, Denmark, Estonia, Finland, Hungary, Ireland, Israel, Italy, Kosovo, Latvia, Lithuania, Norway, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, and Sweden.
Agendia Inc. (U.S.)
Founded in 2003 and headquartered in California, U.S., Agendia Inc. is a molecular diagnostics company providing solutions for treating breast cancer. The company has two key product offerings, MammaPrint and BluePrint tests, which analyze crucial genes related to breast cancer recurrence. Its primary focus is on breast cancer, providing genomic insights to healthcare professionals to facilitate accurate treatment decisions. For customers outside the Americas, the company delivers its products through Agendia N.V. (Netherlands).
Personalis, Inc. (U.S.)
Founded in 2011 and headquartered in California, U.S., Personalis, Inc. specializes in developing comprehensive genomic tests with actionable insights. These products are tailored to detect recurrences at the earliest stages, facilitating the selection of targeted therapies through extensive genomic profiling and advanced biomarker strategies for drug development. The company operates within a single reportable segment: Sale of Sequencing and Data Analysis Services.
The company offerings enable customers to perform advanced cancer genomic tests that are performed by the NeXT Platform. Furthermore, research-focused products, including transcriptome sequencing, exome sequencing, and targeted cancer panels, are performed on the ACE Platform, the predecessor to NeXT. The company offers WGS for several population sequencing projects and research applications.
Some of the company’s key customers include diagnostics companies, pharmaceutical companies, biopharmaceutical companies, universities, healthcare providers, non-profits, and government entities. The key subsidiaries of the company are Personalis (UK) Ltd. (U.K.) and Shanghai Personalis Biotechnology Co., Ltd. (China).
Exact Sciences Corporation (U.S.)
Founded in 1995 and headquartered in Wisconsin, U.S., Exact Sciences Corporation is a company that provides advanced cancer diagnostics solutions. The company’s products and services provide solutions for screening and precision oncology.
The company operates through a single reportable segment and reports revenue from different sources, including screening, precision oncology, and COVID-19 testing. The company operates throughout the U.S., Canada, Japan, and eight other European countries and provides its Oncotype tests in over 90 countries.
Popular Mention: Genomic Health, Inc. (U.S.), Exact Sciences Laboratories, LLC (U.S.), and Exact Sciences Thrive, LLC (U.S.).
Authoritative Research on the Cancer/Tumor Profiling Market – Global Opportunity Analysis and Industry Forecast (2023-2030)
Need more information? Meticulous Research®’s new report covers each of these companies in much more detail, providing analysis on the following:
- Recent financial performance
- Key products
- Significant company strategies
- Partnerships and acquisitions
The Comprehensive report provides global market size estimates, market share analysis, revenue numbers, and coverage of key issues and trends.